Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG
regimen in the treatment of relapsed or refractory acute myeloid leukemia